(Q51712533)

10 April 2018

editorial

0 references

title

Evaluating the feasibility of lantibiotics as an alternative therapy against bacterial infections in humans. (English)

1 reference

10 April 2018

author name string

Auke Johan van Heel

series ordinal

1

1 reference

10 April 2018

Manuel Montalban-Lopez

series ordinal

2

1 reference

10 April 2018

Oscar P Kuipers

series ordinal

3

1 reference

10 April 2018

language of work or name

English

0 references

publication date

27 April 2011

1 reference

10 April 2018

Expert Opinion on Drug Metabolism & Toxicology

published in

1 reference

10 April 2018

volume

7

1 reference

10 April 2018

issue

6

1 reference

10 April 2018

page(s)

675-680

1 reference

10 April 2018

Origins and evolution of antibiotic resistance

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Biosynthesis, immunity, regulation, mode of action and engineering of the model lantibiotic nisin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Lantibiotics: peptides of diverse structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Structure and biological activity of chemically modified nisin A species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Nisin resistance of Streptococcus bovis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Pharmacodynamic activity of the lantibiotic MU1140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

The bacteriocin nisin, an effective agent for the treatment of staphylococcal mastitis during lactation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

BAGEL2: mining for bacteriocins in genomic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Inhalation of Moli1901 in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Development and validation of a LC-MS quantification method for the lantibiotic MU1140 in rat plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Human serum binding and its effect on the pharmacodynamics of the lantibiotic MU1140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

A 90-day oral toxicity study of nisin A, an anti-microbial peptide derived from Lactococcus lactis subsp. lactis, in F344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Evaluation of developmental toxicity of microbicide Nisin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Enterococcal cytolysin: a novel two component peptide system that serves as a bacterial defense against eukaryotic and prokaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Isolation of a variant of subtilosin A with hemolytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Contraceptive efficacy of antimicrobial peptide Nisin: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Evaluation of antimicrobial peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Interaction of contraceptive antimicrobial peptide nisin with target cell membranes: implications for use as vaginal microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

A phase I trial of intranasal Moli1901 for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

MICs of mutacin B-Ny266, nisin A, vancomycin, and oxacillin against bacterial pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.573478

10.1517/17425255.2011.573478

21 January 2018

Identifiers

DOI

1 reference

10 April 2018

1 reference

10 April 2018